Tisch, Carmen; Xourgia, Eleni; Exadaktylos, Aristomenis; Ziaka, Mairi (2024). Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19. (In Press). Endocrine Springer 10.1007/s12020-024-03758-8
|
Text
s12020-024-03758-8.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (915kB) | Preview |
OBJECTIVE
SGLT-2i are increasingly recognized for their benefits in patients with cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications in acute illnesses, including COVID-19. This systematic review aims to evaluate the effects of SGLT-2i in patients facing acute illness, particularly focusing on SARS-CoV-2 infection.
METHODS
Following PRISMA guidelines, a systematic search of PubMed, Scopus, medRxiv, Research Square, and Google Scholar identified 22 studies meeting inclusion criteria, including randomized controlled trials and observational studies. Data extraction and quality assessment were conducted independently.
RESULTS
Out of the 22 studies included in the review, six reported reduced mortality in DM-2 patients taking SGLT-2i, while two found a decreased risk of hospitalization. Moreover, one study demonstrated a lower in-hospital mortality rate in DM-2 patients under combined therapy of metformin plus SGLT-2i. However, three studies showed a neutral effect on the risk of hospitalization. No increased risk of developing COVID-19 was associated with SGLT-2i use in DM-2 patients. Prior use of SGLT-2i was not associated with ICU admission and need for MV. The risk of acute kidney injury showed variability, with inconsistent evidence regarding diabetic ketoacidosis.
CONCLUSION
Our systematic review reveals mixed findings on the efficacy of SGLT-2i use in COVID-19 patients with cardiometabolic risk factors. While some studies suggest potential benefits in reducing mortality and hospitalizations, others report inconclusive results. Further research is needed to clarify optimal usage and mitigate associated risks, emphasizing caution in clinical interpretation.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > University Emergency Center 04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Xourgia, Eleni, Exadaktylos, Aristomenis |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1559-0100 |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
07 Mar 2024 10:43 |
Last Modified: |
08 Mar 2024 02:43 |
Publisher DOI: |
10.1007/s12020-024-03758-8 |
PubMed ID: |
38448675 |
Uncontrolled Keywords: |
Acute Illness COVID-19 Diabetic Ketoacidosis Intensive Care Unit Mechanical Ventilation SGLT-2 Inhibitors |
BORIS DOI: |
10.48350/193932 |
URI: |
https://boris.unibe.ch/id/eprint/193932 |
Actions (login required)
 |
Edit item |